Researchers from the Canada North Concussion Network in Manitoba investigated the frequency of vestibulo-ocular dysfunction in children and adolescents with sports-related concussion and found that…
Smartphone App Shows Promise for Visual Acuity Testing
A smartphone-based application was comparable to standard charts used for visual acuity testing in a new study. Medscape Medical News
Uncategorized
Technology the latest addition to OSN Editorial Board
It is my pleasure to introduce the new Technology Section to the Ocular Surgery News Editorial Board, along with the new Technology Section Editor William B. Trattler, MD. With so many emerging tools and evolving technology in ophthalmology, we set out to create a new section of early adopters to help keep readers informed of the latest advances in ophthalmology. The mission of the new section under Dr. Trattler’s leadership is not to review new technology, but to analyze and discuss the latest technologies and the best way to implement (Read more...)
Uncategorized
EYE TECH CARE在中國發展業務，成為其全球擴張的一部分
法國RILLIEUX-LA-PAPE–(BUSINESS WIRE)–(美國商業資訊) — EYE TECH CARE SA (ETC)是開發和行銷眼科無創治療醫療器材的公司，該公司今天宣佈，其用於治療青光眼的創新系統EyeOP1®已獲得中國食品藥品監督管理局(CFDA)的醫療器械分類，開始審核流程。 繼EyeOP1®在歐洲和美國（EYE TECH CARE的主要目標市場）上市之後，中國成為該公司的關鍵市場：中國青光眼患者有2200萬人，占全球青光眼病例人數的28% (MarketScope 2014)。這些患者中多數為晚期青光眼，需要手術治療，由於手術步驟和病情的複雜性，手術後可導致各種併發症，手術需要由受過專科訓練的外科醫師在專科治療機構中進行。 EyeOP1®是ETC開發的創新醫學解決方案，用於治療青光眼，可替代手術治療。它可用於所有青光眼未獲控制的患者，無論患者既往是否接受過治療，可完全符合中國市場的需求。該治療為門診手術，可顯著降低眼內壓。該手術的原理是對睫狀體進行超音波處理（即手術治療），使眼睛的這一部位產生精確定位的輕微凝固，從而減少水性體液的生成。對醫師而言，該
Scientists identify gene mutation that causes color blindness
A rare eye disorder marked by color blindness, light sensitivity, and other vision problems can result from a newly discovered gene mutation identified by an international research team, including scientists from Columbia University Medical Center.
Uncategorized
Ocular Therapeutix, Inc. Announces Proposed Public Offering of Common Stock
BEDFORD, Mass.–(BUSINESS WIRE)–Ocular Therapeutix, Inc. (NASDAQ: OCUL) announced today that it has commenced an underwritten public offering of 4,000,000 shares of its common stock. The offering consists of 3,200,000 shares being offered by the Compa…